These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1883550)

  • 1. Gp160 of commercial HIV western blots is not gp160env. Should criteria for seropositivity be revised?
    Fenouillet E; Blanes N; Gluckman JC
    AIDS; 1991 Jun; 5(6):770. PubMed ID: 1883550
    [No Abstract]   [Full Text] [Related]  

  • 2. [Diagnostic value of antibodies against HIV-1 proteins in seropositive drug addicts tested by the western blotting method].
    Swiderska H; Kalinowska B
    Przegl Epidemiol; 1992; 46(1-2):19-25. PubMed ID: 1475386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Dis Markers; 1991; 9(1):51. PubMed ID: 1742945
    [No Abstract]   [Full Text] [Related]  

  • 4. Which gp160 vaccine?
    Moore J; Lewis GK; Robinson J
    Nature; 1993 Feb; 361(6412):503. PubMed ID: 7679205
    [No Abstract]   [Full Text] [Related]  

  • 5. The presence or absence of gp120/gp160 bands on indeterminate western blots: predictive value for HIV seroconversion.
    King R; Frey S; Beisha R; Van de Perre P; Karita E; Allen S
    AIDS; 1993 Mar; 7(3):437-8. PubMed ID: 8471210
    [No Abstract]   [Full Text] [Related]  

  • 6. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzyme immunoassay using native envelope glycoprotein (gp160) for detection of human immunodeficiency virus type 1 antibodies.
    Nair BC; Ford G; Kalyanaraman VS; Zafari M; Fang C; Sarngadharan MG
    J Clin Microbiol; 1994 Jun; 32(6):1449-56. PubMed ID: 8077388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two additional AIDS vaccines approved for clinical trials.
    J Am Osteopath Assoc; 1991 May; 91(5):433. PubMed ID: 2061098
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of a new dot blot assay for confirmation of human immunodeficiency virus type 1 and 2 infections using recombinant p24, gp41, gp120 and gp36 antigens.
    Ravanshad M; Sabahi F; Mahboudi F; Kazemnejad A
    Saudi Med J; 2006 Jan; 27(1):31-6. PubMed ID: 16432590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive response. Encouraging results in the search for an AIDS vaccine.
    Beardsley T
    Sci Am; 1991 Aug; 265(2):26. PubMed ID: 1862329
    [No Abstract]   [Full Text] [Related]  

  • 14. Human trials of AIDS vaccines: current status and future directions.
    Koff WC; Fauci AS
    AIDS; 1989; 3 Suppl 1():S125-9. PubMed ID: 2558684
    [No Abstract]   [Full Text] [Related]  

  • 15. The envelope of HIV-1 as a key component to infectivity.
    Buchbinder A
    Prog AIDS Pathol; 1990; 2():1-11. PubMed ID: 2103853
    [No Abstract]   [Full Text] [Related]  

  • 16. Normal T cell receptor-mediated signaling in T cell lines stably expressing HIV-1 envelope glycoproteins.
    Tani Y; Tian H; Lane HC; Cohen DI
    J Immunol; 1993 Dec; 151(12):7337-48. PubMed ID: 7903106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 18. Recognition of human immunodeficiency virus glycoproteins by natural anti-carbohydrate antibodies in human serum.
    Tomiyama T; Lake D; Masuho Y; Hersh EM
    Biochem Biophys Res Commun; 1991 May; 177(1):279-85. PubMed ID: 2043114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of antibodies to p24 and gp41 epitopes of HIV by ELISA using the recombinant core protein (p24) and envelope synthetic protein (gp41).
    Filice G; Soldini L; Orsolini P; Razzini E; Chiapparoli L; Gulminetti R; Cattaneo E; Achilli G
    Microbiologica; 1991 Jan; 14(1):1-7. PubMed ID: 1906127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS vaccine boosts immunity in HIV patients.
    RN; 1991 Oct; 54(10):103. PubMed ID: 1925340
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.